• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Medtronic’s US$700 Million Robotics Push With Cornerstone Reshaping The Investment Case For MDT?

    Simply Wall St·09/05/2026 03:25:37
    Listen to the news
    • In early September 2026, Medtronic reported first-quarter sales of US$9,756 million and net income of US$1,470 million, announced a roughly US$700 million partnership with Cornerstone Robotics to distribute the Sentire surgical system alongside its Hugo platform outside the U.S., and named Masooma Sandeep Head of Communications for the TURMECA Region-led Markets.
    • Together, the strong quarterly results, the expanded robotic-assisted surgery offering through Cornerstone Robotics’ Sentire system, and strengthened regional communications leadership highlight Medtronic’s focus on scaling its technology ecosystem and presence across growth markets.
    • We’ll now assess how Medtronic’s US$700 million Cornerstone Robotics partnership could influence its existing investment narrative around robotics and growth.

    AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    Medtronic Investment Narrative Recap

    To hold Medtronic, you generally need to believe it can turn its broad medtech portfolio and heavy R&D spend into steadily improving margins and earnings, despite pressure in underperforming units like U.S. Diabetes and parts of MedSurg. The latest quarter’s higher sales and earnings support that thesis, but the roughly US$700 million Sentire partnership also raises the execution bar in robotics, which remains both a key near term catalyst and a major operational risk.

    The Cornerstone Robotics agreement is the most relevant recent development here, because it sits directly on top of Medtronic’s Hugo platform and wider connected surgical ecosystem. By distributing Sentire alongside Hugo outside the U.S., Medtronic is leaning harder into robotic assisted surgery as a growth driver, which could amplify the impact of any manufacturing, regulatory or adoption issues in its robotics pipeline on future revenue and profit trends.

    Yet even with this expanding robotics push, investors should be aware that...

    Read the full narrative on Medtronic (it's free!)

    Medtronic’s narrative projects $41.5 billion revenue and $6.6 billion earnings by 2029. This requires 4.5% yearly revenue growth and a $1.8 billion earnings increase from $4.8 billion today.

    Uncover how Medtronic's forecasts yield a $98.00 fair value, a 4% upside to its current price.

    Exploring Other Perspectives

    MDT 1-Year Stock Price Chart
    MDT 1-Year Stock Price Chart

    Some analysts were already optimistic, assuming revenue could reach about US$44.1 billion and earnings US$7.1 billion by 2029, so this new Medtronic Cornerstone tie up might either reinforce that upbeat view or highlight how much depends on Hugo and Sentire gaining real traction in surgical robotics.

    Explore 7 other fair value estimates on Medtronic - why the stock might be worth as much as 13% more than the current price!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your Medtronic research is our analysis highlighting 5 key rewards that could impact your investment decision.
    • Our free Medtronic research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Medtronic's overall financial health at a glance.

    No Opportunity In Medtronic?

    Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.